TD Cowen downgrades Sarepta rating and cuts PT due to FDA pullback risk for Elevidys.

From Investing.com: 2025-06-17 23:56:00

TD Cowen has downgraded Sarepta’s rating and reduced its price target due to concerns over potential FDA pullback risk for Elevidys, a gene therapy targeting Duchenne muscular dystrophy. This decision comes after the FDA requested additional information on the drug’s manufacturing process, causing uncertainty for investors.



Read more at Investing.com: Sarepta: TD Cowen downgrades rating, cuts PT on FDA pullback risk for Elevidys